All In Biotech

Drug Trial Radar · NCT00286169

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Apr 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

130

Planned (sponsor's estimate)

Start

Apr 2006

Primary completion

Not stated

Sponsor

Lead sponsor
Sumitomo Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 3, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and toxicity of amrubicin with carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer.

Conditions

  • Small-cell Lung Cancer

Interventions

  • Amrubicin HydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Chubu Region Site

    Chūbu, Japan

  • Chugoku Region Site

    Chugoku, Japan

  • Hokkaido Region Site

    Hokkaido, Japan

  • Kanto Region Site

    Kanto, Japan

  • Kinki Region Site

    Kinki, Japan

  • Kyushu Region Site

    Kyushu, Japan

  • Shikoku Region Site

    Shikoku, Japan

  • Tohoku Region Site

    Tōhoku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.